Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(60%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_2
5
100%

Phase Distribution

0

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
5(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Completed(1)

Detailed Status

Recruiting2
Not yet recruiting1
Completed1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 25 (100.0%)

Trials by Status

not_yet_recruiting120%
recruiting240%
completed120%
active_not_recruiting120%

Recent Activity

3 active trials
Showing 5 of 5
recruitingphase_2

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

NCT06179303
not_yet_recruitingphase_2

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

NCT07466498
active_not_recruitingphase_2

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

NCT02949284
recruitingphase_2

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

NCT06369610
completedphase_2

Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer

NCT03279250

Clinical Trials (5)

Showing 5 of 5 trials
NCT06179303Phase 2

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Recruiting
NCT07466498Phase 2

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

Not Yet Recruiting
NCT02949284Phase 2

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Active Not Recruiting
NCT06369610Phase 2

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

Recruiting
NCT03279250Phase 2

Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer

Completed

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5